An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pazopanib (Primary) ; Cisplatin
Indications Advanced breast cancer; HER2 positive breast cancer; Solid tumours
Focus Adverse reactions
Acronyms PACIFIK

16 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
15 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
25 Jul 2010 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com